The prognostic value of T1 mapping and late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with light chain amyloidosis

Table 2 Univariate and multivariate Cox proportional hazard analysis in all AL amyloidosis patients

	Univariate		Multivariate		Multivariate
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age, per 1 year increase	1.059 (1.008–1.112)	0.023	1.082 (1.022–1.144)	0.006	1.063 (1.000–1.129)	0.051
NYHA	2.534 (1.581–4.062)	0.001	1.569 (0.880–2.797)	0.127	2.253 (1.385–3.666)	0.001
log (cTnI), per unit increase	2.568 (1.204–5.477)	0.015	–	–	–	–
log (NT-proBNP), per unit increase	3.122 (1.501–6.496)	0.002	–	–	–	–
Mayo Stage	2.111 (1.323–3.368)	0.002	1.121 (0.603–2.081)	0.718	1.525 (0.846–2.748)	0.16
E/E’, per 1 unit increase	1.089 (1.012–1.110)	0.045	1.783 (0.334–9.501)	0.498	1.722 (0.318–9.267)	0.43
LVEF, per 1% increase	0.961 (0.936–0.986)	0.003	0.982 (0.948–1.017)	0.307	0.983 (0.951–1.017)	0.33
Septal thickness, per 1 mm increase	1.132 (1.040–1.232)	0.004	1.175 (1.035–1.335)	0.013	1.130 (1.018–1.255)	0.022
ECV ≥44.0%	7.677 (2.256–26.128)	0.001	7.249 (2.039–25.771)	0.002	–	–
Global LGE	5.047 (1.971–12.926)	0.001	–	–	4.804 (1.751–13.179)	0.002

All significantly prognostic factors in univariate analysis were listed. Univariate analysis was not performed for native T1 because the Kaplan-Meier curves crossed each other (Tarone-Ware, P = 0.069). All clinically and statistically significant variates in univariate analysis were put into the multivariate Cox model, except for log (cTnI) and log (NT-proBNP), as they were included in Mayo Stage. ECV and LGE were put in separate models because of a correlation ρ of 0.889. Backward regression was chosen
HR Hazard ratio, CI Confidence interval, NYHA New York Heart Association, cTnI Cardiac Troponin I, NT-proBNP N-terminal pro-B-type natriuretic peptide LVEF Left ventricle ejection fraction, LGE Late gadolinium enhancement, ECV Extracellular volume

ISSN: 1532-429X